|
|
Exchange: |
Nasdaq Small Cap |
Security
Type: |
Common |
Shares
Out: |
173,744,000 |
Market
Cap: |
1.13(B) |
Last
Volume: |
148,509 |
Avg
Vol: |
0 |
52
Week Range: |
$6.56 - $15.45 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Health Services |
Level
III Sector: |
Medical Laboratories & Research |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : 8.3 |
Insider 6 Months : 8.3 |
Insider 3/6 Months : 16.7 |
|
Guru Rank Number : 607 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Ironwood Pharmaceuticals is a gastrointestinal (GI) healthcare company focusing on developing the treatment of GI diseases. LINZESS® (linaclotide), Co.'s commercial product, is a product in a class of GI medicines called guanylate cyclase type C agonists and is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). LINZESS is available to adult men and women suffering from IBS-C or CIC in the U.S. and Mexico and to adult men and women suffering from IBS-C in Japan and China. Co. has partnerships with pharmaceutical companies to support the development and commercialization of linaclotide.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
17,604 |
17,604 |
53,676 |
53,676 |
Total Buy Value |
$160,420 |
$160,420 |
$460,539 |
$460,539 |
Total People Bought |
2 |
2 |
2 |
2 |
Total Buy Transactions |
2 |
2 |
3 |
3 |
Total Shares Sold |
0 |
294,129 |
382,411 |
1,047,483 |
Total Sell Value |
$0 |
$4,424,082 |
$5,332,221 |
$12,970,668 |
Total People Sold |
0 |
6 |
6 |
9 |
Total Sell Transactions |
0 |
7 |
13 |
48 |
End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Mcguire Terrance |
Director |
|
2016-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
23,674 |
43,891 |
|
- |
|
Mchugh Julie |
Director |
|
2016-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
23,674 |
66,783 |
|
- |
|
Olanoff Lawrence S |
Director |
|
2016-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
23,674 |
34,705 |
|
- |
|
Owens Edward P |
Director |
|
2016-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
23,674 |
167,680 |
|
- |
|
Fanucci Marsha |
Director |
|
2016-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
23,674 |
60,008 |
|
- |
|
Gilbert Halley E |
Chief Legal Officer |
|
2016-05-25 |
4 |
AS |
$12.19 |
$247,152 |
D/D |
(20,275) |
64,537 |
|
- |
|
Gilbert Halley E |
Chief Legal Officer |
|
2016-05-25 |
4 |
OE |
$3.76 |
$59,652 |
D/D |
15,865 |
10,000 |
|
- |
|
Dreyfus Andrew |
Director |
|
2016-04-06 |
4 |
A |
$0.00 |
$0 |
D/D |
2,585 |
2,585 |
|
- |
|
Mcguire Terrance |
Director |
|
2016-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
239 |
20,217 |
|
- |
|
Walsh Christopher T Phd |
Director |
|
2016-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
239 |
47,160 |
|
- |
|
Hecht Peter M |
Chief Executive Officer |
|
2016-03-11 |
4 |
AS |
$10.66 |
$426,400 |
D/D |
(40,000) |
4,670,322 |
|
- |
|
Hecht Peter M |
Chief Executive Officer |
|
2016-03-11 |
4 |
OE |
$1.56 |
$62,400 |
D/D |
40,000 |
4,710,322 |
|
- |
|
Hecht Peter M |
Chief Executive Officer |
|
2016-03-10 |
4 |
AS |
$10.63 |
$425,200 |
D/D |
(40,000) |
4,670,322 |
|
- |
|
Hecht Peter M |
Chief Executive Officer |
|
2016-03-10 |
4 |
OE |
$1.56 |
$62,400 |
D/D |
40,000 |
4,710,322 |
|
- |
|
Hecht Peter M |
Chief Executive Officer |
|
2016-03-09 |
4 |
AS |
$10.87 |
$434,800 |
D/D |
(40,000) |
4,670,322 |
|
- |
|
Hecht Peter M |
Chief Executive Officer |
|
2016-03-09 |
4 |
OE |
$1.56 |
$344,432 |
D/D |
220,790 |
4,710,322 |
|
- |
|
Currie Mark G |
Chief Scientific Officer |
|
2016-03-09 |
4 |
OE |
$1.56 |
$251,001 |
D/D |
160,898 |
385,000 |
|
- |
|
Currie Mark G |
Chief Scientific Officer |
|
2016-03-09 |
4 |
AS |
$10.86 |
$1,629,000 |
D/D |
(150,000) |
374,102 |
|
- |
|
Olanoff Lawrence S |
Director |
|
2016-03-07 |
4 |
AS |
$11.11 |
$24,442 |
D/D |
(2,200) |
11,031 |
|
- |
|
Consylman Gina |
Chief Accounting Officer |
|
2016-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
21,330 |
|
- |
|
Gilbert Halley E |
Chief Legal Officer |
|
2016-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
32,500 |
68,947 |
|
- |
|
Graney Thomas |
Chief Financial Officer |
|
2016-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
17,500 |
22,637 |
|
- |
|
Consylman Gina |
Chief Accounting Officer |
|
2016-02-24 |
4 |
AS |
$8.50 |
$3,570 |
D/D |
(420) |
6,330 |
|
- |
|
Mccourt Thomas A |
Chief Commercial Officer |
|
2016-02-24 |
4 |
AS |
$8.50 |
$13,600 |
D/D |
(1,600) |
27,312 |
|
- |
|
Currie Mark G |
Chief Scientific Officer |
|
2016-02-24 |
4 |
AS |
$8.50 |
$1,297,809 |
D/D |
(152,154) |
374,102 |
|
- |
|
914 Records found
|
|
Page 19 of 37 |
|
|